Terapia innovativa: oltre il PEB? Relatore: Dr ... - Oncologia Rimini
Terapia innovativa: oltre il PEB? Relatore: Dr ... - Oncologia Rimini
Terapia innovativa: oltre il PEB? Relatore: Dr ... - Oncologia Rimini
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Prognostic factors in relapsed or refractory germ-cell tumors<br />
ASCO 2009 - Abstr # 5030<br />
A. Lorch, J. Beyer , C. Mollevi, M. Guerra, A. Kramar for the International Group on<br />
Prognostic Factors in Relapsed or Refractory Germ-Cell Tumors<br />
1.00<br />
Progression-Free Survival<br />
Probab<strong>il</strong>ity<br />
0.75<br />
0.50<br />
0.25<br />
0.00<br />
Very low (score -1)<br />
Low (score 0)<br />
Intemrediate (score 1 or 2)<br />
High (score 3 or 4)<br />
Very high (score >5)<br />
Number at risk<br />
Very Low<br />
Low<br />
Intermediate<br />
High<br />
Very High<br />
0 1 2 3 4<br />
Years<br />
76 54 47 37 0<br />
257 156 124 102 85<br />
646 309 244 200 164<br />
351 94 80 58 45<br />
105 14 10 8 0<br />
V Low Low Interm. High V High<br />
Conclusion<br />
Prognostic variables significantly influence PFS of rr-GCP and<br />
can predict the risk of progression after salvage treatment.
Change language